Shmulik Hess

SciGen Pte Ltd. engages in the development, manufacturing, and marketing of biopharmaceutical products. It operates through following segments: Singapore, Australia, Korea, Thailand, Philippines, China, and Others. The Singapore segment comprises of corporate office functions, sales, and marketing. The Australia, Korea, Thailand, and Philippines segments deal with sales and marketing activities. The China segment is involved in regulatory activities. The Others segment covers operations on in Indonesia, Pakistan, Vietnam, Hong Kong, Myanmar, Malaysia, and profit sharing income on sale of insulin. The firm's products include SciLin, SciTropin A, SciLocyte, SciTrace 5 Injection, and Heri Injection. The company was founded by Saul Akerib Mashaal in 1988 and is headquartered in Singapore.

Active P Ltd. develops proprietary oral available peptide drugs to treat diabetes. The company was founded by Shmulik Hess, Chaim Gilon, and Amnon Hoffman on September 10, 2008 and is headquartered in Kiryat Shmona, Israel.

Tabby Therapeutics Ltd. develops therapeutic drugs. The company is based in Ness Ziona, Israel. The Israeli company was founded in 2021 by Adi Barzel, Alessio D. Nahmad.